A 28-year-old man undergoes renal transplantation and is prescribed tacrolimus as part of his immunosuppressive regimen. At the 2-week post-transplant follow-up, he complains of tremor, insomnia, and difficulty concentrating. Which investigation is most specific for confirming tacrolimus-related neurotoxicity?

## Investigation of Choice for Tacrolimus Neurotoxicity ### Clinical Context Tacrolimus is a calcineurin inhibitor widely used in transplantation. Neurotoxicity is a dose-dependent adverse effect occurring in 10–25% of transplant recipients, manifesting as tremor, headache, insomnia, confusion, and rarely posterior reversible encephalopathy syndrome (PRES). ### Why Whole Blood Tacrolimus Trough Level? **Key Point:** Tacrolimus neurotoxicity is concentration-dependent. Therapeutic drug monitoring (TDM) via whole blood trough level (C0) is the most specific and practical investigation to confirm drug-related toxicity. **High-Yield:** Whole blood tacrolimus levels >15–20 ng/mL are associated with increased neurotoxicity risk. Measuring C0 (trough level) is standard practice in transplant centers and directly guides dose adjustment. ### Diagnostic Algorithm ```mermaid flowchart TD A[Post-transplant neurological symptoms]:::outcome --> B{Suspect tacrolimus toxicity?}:::decision B -->|Yes| C[Measure whole blood tacrolimus C0]:::action C --> D{Level elevated?}:::decision D -->|Yes| E[Reduce tacrolimus dose]:::action D -->|No| F[Investigate alternative cause]:::action F --> G[MRI brain, EEG if seizures]:::action E --> H[Recheck level in 3-5 days]:::action ``` ### Comparison of Investigations | Investigation | Specificity for Tacrolimus Toxicity | Clinical Use | |---|---|---| | **Whole blood tacrolimus C0** | **High** — directly measures drug exposure | **First-line; guides dose adjustment** | | MRI brain with FLAIR | Low — nonspecific; may show PRES if severe | Severe symptoms; rule out other pathology | | EEG | Low — nonspecific; shows general slowing | Seizures or encephalopathy; not diagnostic | | CSF analysis | Very low — usually normal in tacrolimus toxicity | Infection or inflammation; not indicated | **Clinical Pearl:** Mild tremor and insomnia at therapeutic tacrolimus levels (8–12 ng/mL) may not require dose reduction; patient education and reassurance often suffice. However, elevated levels warrant dose adjustment. ### Why TDM Is Superior - Objective, quantitative measurement of drug exposure - Direct correlation with neurotoxicity risk - Allows rational, personalized dose adjustment - Avoids unnecessary neuroimaging or invasive procedures - Cost-effective and rapid (results within 24 hours) [cite:Harrison 21e Ch 297; KD Tripathi 8e Ch 73]